# Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

> **NCT00445679** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 807 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** DVS SR
- **DRUG:** Paroxetine

## Key facts

- **NCT ID:** NCT00445679
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 807 (ACTUAL)
- **Last updated:** 2013-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445679, "Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00445679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*